All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
MedImmune, which already markets Synagis to prevent respiratory syncytial virus in high-risk infants, made another investment in the RSV space by signing a $112 million deal to develop small-molecule compounds discovered by Australian company Biota Holdings Ltd. (BioWorld Today)